Supplementary

a.

Total COVID-19 Recovered patient cohort	Age	Max	81	Average	53.5
		Min	20		
	Gender	М	38	Total	82
		F	44		
F	Age	Max	78	Average	53.8
		Min	20		
M	Age	Max	81	Average	53
		Min	25		

b.

Follow up COVID-19 Recovered patient cohort	Age	Max	81	Average	50.5
		Min	20		
	Gender	М	47	Total	90
		F	43		
F	Age	Max	78	Average	49
		Min	20		
М	Age	Max	81	Average	53
		Min	25		

c.

Follow up COVID-19 Recovered patient cohort who	Age	Max Min	76 20	Average	48
received one BNT162b2	Condor	М	13	Total	22
mRNA-vaccine dose	Gender	F	9	Total	22
F	Age	Max	76	Average	48
		Min	20		
М	Age	Max	76	Average	52
		Min	28		

Naïve vaccinees	Age	Max	65	Average	43.5
		Min	22		
	Gender	М	4	Total	17
		F	13		
F	Age	Max	65	Average	43.5
		Min	22		
М	Age	Max	63	Average	46
		Min	29		

Table S1 | **Study participant cohorts a**) COVID-19 recovered patients **b**) Follow up recovered patients (sub-cohort of the recovered patients). **c**) Follow up recovered patients that received one BNT162b2 mRNA-vaccine dose. **d**) Naïve vaccinees that received two doses of the BNT162b2 mRNA-vaccine.




Figure. S1 | **Quartile determination utilizing bootstrap method.** RBD⁺ antibody measured values were randomly selected (n=50) out of the extended dataset obtained from all recovered patients (n=345) and quartile thresholds were set according to the mean values derived from 10,000 iterations. Y-Axis in Log₁₀, X-axis represent the number of iterations used in the bootstrapping procedure.




Figure. S2 | **Designation of RBD**⁺ **antibody levels by quartiles.** Measured RBD⁺ antibody levels in recovered patients were designated to their respective quartile (i.e., from low to high Q1-Q4 respectively) according to the measured antibody level at the first visit (V1). Y-axis, Log₁₀ of RBD⁺ antibody levels. X-axis the quartile groups, n indicates the number of individuals assigned to each quartile at V1 for each isotype.